Complications of hemophilia include chronic joint deformities caused by bleeding into the joint or brain hemorrhage. Some children with hemophilia develop antibodies to transfused clotting factors so that the transfusions become ineffective. If antibodies are detected in blood samples, the dosage of the plasma concentrates may be increased, or different types of clotting factors or drugs to reduce the antibody levels may be used.

In the past, plasma concentrates carried the risk of transmitting blood-borne diseases such as hepatitis and AIDS. About 60 percent of people with hemophilia treated with plasma concentrates in the early 1980s were infected with HIV. Today, however, the risk of transmitting HIV infection through plasma concentrates has been virtually eliminated by using screened and processed blood and a genetically engineered clotting factor VIII (Recombinant).

0 0

Post a comment